bioAffinity Prices $4M At-the-Market Private Placement, Adding 8.5M Shares
BIAF is trading near its 52-week low of $0.457 (2.6% above the low) on light trading volume (0.1× avg).
Summary
bioAffinity Technologies announced a $4 million private placement priced at-the-market under Nasdaq rules, selling 8,462,027 shares (or pre-funded warrants) plus warrants for up to 16,924,054 additional shares at a combined effective price of $0.4727 per share. The offering is expected to close August 14, 2026. This follows a $3.2 million public offering closed in June and comes as the stock trades near its 52-week low of $0.4573, with a market cap under $4 million. The at-the-market pricing avoids a discount but the warrant overhang and share count increase are dilutive. Proceeds will likely fund ongoing commercialization of CyPath Lung, which reported 216% volume growth in Q2 but widening net losses. Watch for stockholder approval of warrant exercise and any subsequent registration statement for resale.
Updates
· SEC 8-K — The private placement closed on August 14, 2026, with net proceeds expected to be approximately $3.6 million after fees and expenses.
At the time of this announcement, BIAF was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $0.46 to $13.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.